Abstract 1378P
Background
The management of non-small cell lung cancer (NSCLC) has transformed over the past decade through the development of immunotherapy and targeted therapies. Our objective was to evaluate the gains in survival in stage IV NSCLC by sociodemographic groups in the United States.
Methods
Patients diagnosed with and treated for Stage IV NSCLC between 2010 and 2020 in the National Cancer Database were studied in 3 eras (2010 - 2013, 2014 - 2017, and 2018 - 2020). Unadjusted survival was assessed by Kaplan Meier and stratified cox analysis was performed to evaluate differences in survival by race and ethnicity.
Results
Overall, 374,273 patients were identified. The median survival was highest across all 3 eras for Asians (12.9, 17.0, and 22.5 months) and the lowest for American Indians/Alaskan Natives (6.9, 6.9, and 9.0 months) (Table). Survival increased for all racial/ethnicity groups across eras, consistent with the development of novel therapeutics, but with considerable differences in the proportionality of gains. For example, between era 1 and 3, Hispanics experienced an 81% increase in median survival, while American Indians/Alaskan Natives experienced a 30% increase (Table). Multivariable Cox models also demonstrated considerable variability in mortality risk over time, favoring groups other than non-Hispanic white patients with the exception of American Indians/Alaskan Natives.
Table: 1378P
| 2010-2013 | 2014-2017 | 2018-2020 | |||||
| Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | Median survival | Hazard ratio/P Value | % Difference in median survivalEra 3 &1 | |
| Asian | 12.8 | 0.69 (ConclusionsThere has been a dramatic improvement in survival among stage IV NSCLC over the past decade across all race and ethnicity. The rates of improvement in survival were observed to differ across sociodemographic groups, with the Hispanic patients experiencing the highest benefit. Further studies to understand variability in survival gains by type of therapy or by mutation status are warranted to understand the long-term potential disparities in cancer-related mortality. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyD. Boffa. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest. Resources from the same session1383P - Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based studyPresenter: Dongmei Lin Session: Poster session 06 1384P - Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)Presenter: Yuki Sato Session: Poster session 06 1385P - Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinomaPresenter: Mariana Mancini Session: Poster session 06 1386P - Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKIPresenter: Wei Xin Zhao Session: Poster session 06 1387P - Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UKPresenter: Rubab Batool Session: Poster session 06 1388P - Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315)Presenter: Frank Griesinger Session: Poster session 06 Resources: Abstract 1389P - Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune diseasePresenter: Siddhartha Goutam Session: Poster session 06 1390P - Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumourPresenter: Inès Duparc Session: Poster session 06 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||||